Sector Focus 

Pharma M&A: ready for a resurgence?

Pharma M&A: ready for a resurgence?

Executives at Japanese pharma group Takeda (Jap:4502) and its British peer Shire (SHP) seem to like catchy, date-driven targets. Takeda is working towards its Vision 2025. Shire was aiming for sales of $20bn (£14bn) by 2020 (although this target has since been lessened to the less-catchy “between $17bn and $18bn”). It suggests they might get along well.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now